4 December 2024

VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity...

Read more

25 October 2024

VIVEbiotech publishes new research paper

We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing...

Read more

24 October 2024

Active participation of VIVEbiotech at the ESGCT´s 31st annual meeting

The European Society of Gene and Cell Therapy´s annual congress is in full swing.

Read more

10 October 2024

VIVEbiotech participates one more year in the Innovative Therapies Days

VIVEbiotech is participating as a Silver Sponsor in Innovative Therapies Days, a 2-day conference that takes place every year in Besançon, in the R...

Read more

8 October 2024

VIVEbiotech participates in Cell & Gene Meeting on the Mesa

As in several past editions, VIVEbiotech is participating in Cell & Gene Meeting on the Mesa.

Read more

18 September 2024

Q&A in GEN with Natalia Elizalde

Natalia Elizalde, our Chief Business Development Officer at VIVEbiotech, recently shared her expertise with GEN on the increasing demand for lentiviral vectors, of which we...

Read more

11 September 2024

VIVEbiotech participates in Advanced Therapies Europe

Natalia Elizalde, Chief Business Development Officer of VIVEbiotech, is participating in Phacilitate's Advanced Therapies Europe conference.

Read more

9 September 2024

VIVEbiotech achieves renewal of CIR certification

For the seventh consecutive year and also for the next two, VIVEbiotech has been certified with the CIR – Crédit d´Impôt Recherche certificate.

Read more

28 August 2024

New scientific paper in Viruses

VIVEbiotech has published a scientific paper in the journal Viruses

Read more

23 August 2024

Enhancing global access to advanced therapies: VIVEbiotech’s role in optimizing production and reducing costs

VIVEbiotech has participated in a second roundtable in Pharma's Almanac entitled “How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?”.

Read more